Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BPI-361175 in advanced NSCLC
NCT05329298Phase 2Unknown
- Sponsor
- Betta Pharmaceuticals
- Start
- Jul 2021
- Primary completion
- Jun 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of BPI-361175 in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Betta Pharmaceuticals. Primary endpoints: Adverse Events at 24 months, Recommended Phase II Dose at 24 months and 1 more. Status: unknown.
02
Drugs
BPI-361175
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05329298.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05329298.